DECIMMUNE - Key Persons
Job Titles:
- President
- Managing Director, HealthCare Ventures
Dr. Mirabelli joined HealthCare Ventures in 2000 and is a Managing Director at the firm. Dr. Mirabelli was Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. Dr. Mirabelli was also a co-founder of Isis Pharmaceuticals and served with SmithKline and French Laboratories R&D Division. Dr. Mirabelli received his doctorate in molecular pharmacology from Baylor College of Medicine.
Mr. Hoey brings more than 20 years of executive-level experience in business development, licensing, strategic planning, and financing for technology companies. He has completed over $400 million in corporate partnering transactions and equity financings in the United States, Europe, and Japan and has secured extensive contracts for government sponsored research.
Job Titles:
- Professor of Surgery, Harvard Medical School / Chief, Division of General and Gastrointestinal Surgery, Brigham and Women 's Hospital
Dr. Moore holds the Francis D. Moore Chair of Surgery at Harvard. He graduated from Harvard College and Harvard Medical School, with internship and residency in Surgery at the Peter Bent Brigham Hospital and Brigham and Women's Hospital, respectively. During surgery training, he also completed two years of research training in Immunology with Drs. K. Frank Austen and Douglas Fearon, concentrating on the basic biology of the complement system. Since joining the attending staff in surgery at Brigham and Women's in 1984, he has pursued a vigorous investigational program, as well as developing a busy clinical enterprise of some 20 general surgeons on- and off-site. He is in his 17th year as P.I. of a P50 Trauma Center grant, funded by NIGMS. His long-term specific research interest has been the autologous inflammatory amplification of injury and the use of that research knowledge to lessen the impact of injury on human patients.
Job Titles:
- Professor of Pediatrics and Pathology, Harvard Medical School / Senior Investigator Immune Disease Institute
Dr. Carroll received his PhD from the University of Texas Southwestern Medical School in Dallas in 1980 where he studied the biochemistry and genetics of the complement system in the laboratory of Don Capra. He subsequently joined the laboratory of Dr. Rodney Porter in the Department of Biochemistry at Oxford University, UK where he cloned the first human complement gene (complement C4). In 1985, he was recruited to Children's Hospital and Harvard Medical School in Boston where he now serves as the Senior Investigator at the Immune Disease Institute and Professor of Pediatrics in the Program in Cellular and Molecular Medicine at Children's Hospital and Harvard Medical School. Dr. Carroll also serves as Director of the Graduate Program in Immunology at Harvard University. He is the author of over 150 peer -reviewed articles and his research currently focuses on how the innate immune system regulates the adaptive response to viral and bacterial infection, autoimmunity and inflammation.
Dr. Newman, a graduate of Columbia University's undergraduate and graduate programs with a degree in immunology, led drug discovery at LeukoSite and Critical Therapeutics where he helped bring multiple antibody and small molecule candidates into clinical trials. LeukoSite's efforts resulted in two approved monoclonal therapeutics, alemtuzumab and vedolizumab. In addition he was the founding CSO at Proteostasis Therapeutics. Prior to that, Dr Newman had senior roles in drug discovery at both Ortho Pharmaceuticals and Otsuka America Pharmaceuticals, subsequent to an academic career at the Fred Hutchinson Cancer Research Center. He has co-authored over eighty scientific articles in peer-reviewed journals.